The diagnosis of CM-AVM is established by a heterozygous pathogenic variant in Ephrin-Typ-B-Rezeptor 4 (EPHB4) or RAS p21 Protein Activator 1 (RASA1) identified by molecular genetic testing. Here, RASA1 is linked to cutaneous mastocytosis.